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We evaluated a 32-year-old woman whose oculocutaneous albinism (OCA), bleeding diathesis, neutropenia,
and history of recurrent infections prompted consideration of the diagnosis of Hermansky–Pudlak syndrome
type 2. This was ruled out because of the presence of platelet d-granules and absence of AP3B1 mutations. As
parental consanguinity suggested an autosomal recessive mode of inheritance, we employed homozygosity
mapping, followed by whole-exome sequencing, to identify two candidate disease-causing genes, SLC45A2 and
G6PC3. Conventional dideoxy sequencing confirmed pathogenic mutations in SLC45A2, associated with OCA
type 4 (OCA-4), and G6PC3, associated with neutropenia. The substantial reduction of SLC45A2 protein in the
patient’s melanocytes caused the mislocalization of tyrosinase from melanosomes to the plasma membrane and
also led to the incorporation of tyrosinase into exosomes and secretion into the culture medium, explaining the
hypopigmentation in OCA-4. Our patient’s G6PC3 mRNA expression level was also reduced, leading to
increased apoptosis of her fibroblasts under endoplasmic reticulum stress. To our knowledge, this report
describes the first North American patient with OCA-4, the first culture of human OCA-4 melanocytes, and the
use of homozygosity mapping, followed by whole-exome sequencing, to identify disease-causing mutations in
multiple genes in a single affected individual.
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INTRODUCTION
Until recently, molecular diagnostics for patients with rare
disorders relied upon sequencing of genes identified as
candidates by virtue of the clinical phenotypes. Now,
massively parallel (‘‘next generation’’) sequencing allows
for unfocused detection of disease-causing mutations, with-
out the bias introduced by phenotype. This critical advantage
can be particularly important for patients with clinical
manifestations that point to complex diseases. The process
that is generally employed involves single-nucleotide
polymorphism (SNP) arrays, followed by the next-generation
sequencing technique of whole-exome sequencing (Ng et al.,
2009, 2010; Otto et al., 2010). This reduces the amount of
data generated and is more cost effective than whole-genome
sequencing (Teer and Mullikin, 2010).
We illustrate the benefit of next-generation sequencing in
a patient with oculocutaneous albinism (OCA) and con-
genital neutropenia. OCA is a group of autosomal recessively
inherited hypopigmentary disorders that affect melanin
pigment synthesis or trafficking of pigmentary enzymes or
organelles (King et al., 2002) in the skin, hair, and eyes
(Gronskov et al., 2007). Four genes are associated with OCA:
TYR (OCA-1; Tomita et al., 1989), OCA2 (OCA-2; Rinchik
et al., 1993), TYRP1 (OCA-3; Boissy et al., 1996), and
SLC45A2 (OCA-4; Newton et al., 2001). Mutations in these
genes rarely cause phenotypic features other than albinism,
but certain syndromes have OCA as an obligate component.
Hermansky–Pudlak syndrome (HPS), e.g., is characterized by
OCA and a bleeding diathesis. There are 8 known human
HPS genes (HPS1–8) (Oh et al., 1996; Dell’Angelica et al.,
1999; Anikster et al., 2001; Suzuki et al., 2002; Li et al.,
2003; Zhang et al., 2003; Morgan et al., 2006), whose protein
products are involved in the biogenesis of lysosome-related
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organelles (Huizing et al., 2008). HPS commonly has other
phenotypic features such as pulmonary fibrosis, which is
associated with subtypes 1 and 4 (Oh et al., 1996; Suzuki
et al., 2002).
Congenital neutropenia is a heterogeneous group
of hereditary disorders characterized by life-threatening
bacterial infections early in life due to a paucity of mature
neutrophils (Welte et al., 2006; Boztug et al., 2008).
Mutations in several genes, including ELA2, HAX1, WAS,
GFI1, and recently G6PC3 (Horwitz et al., 1999; Devriendt
et al., 2001; Person et al., 2003; Klein et al., 2007; Boztug
et al., 2009), cause such conditions. Neutropenia also occurs
in patients with HPS-2 disease, due to mutations in AP3B1,
which encodes the b-3A subunit of adaptor complex-3
(Dell’Angelica et al., 1999). Most congenitally neutropenic
patients, including those with HPS-2, respond to recombinant
human granulocyte colony-stimulating factor, which
increases neutrophil counts and decreases the number and
severity of infections (Bonilla et al., 1989).
In this article, we describe a patient of consanguineous
parentage who presented with findings that suggested the
possible diagnosis of HPS-2, i.e., OCA and neutropenia.
When no mutations were found in AP3B1, we performed
homozygosity mapping on a SNP array and whole-exome
sequencing using the patient’s genomic DNA. This allowed
us to identify disease-causing mutations in two different
disease-associated genes, i.e., SLC45A2 causing OCA-4 and
G6PC3 causing neutropenia. Neither of these genes would
have been pursued according to standard practice. We
conclude that SNP array analysis, along with whole-exome
sequencing, can be useful in identifying disease-causing
mutations in a single affected individual, especially if the
family is consanguineous and suitable for homozygosity
mapping.
RESULTS
Case report
A 32-year-old Caucasian female presented to the National
Institutes of Health (NIH) Clinical Center with a history of
inflammatory bowel disease, primary neutropenia and
thrombocytopenia, and a surgically repaired atrial septal
defect. Her medical history revealed that she was diagnosed
with OCA shortly after birth, and subsequent eye examina-
tions confirmed the presence of ocular albinism (Figure 1a).
The patient was hospitalized for E. coli sepsis in the neonatal
period with a white cell count as high as 12K ml1; her
platelet count was 130K ml1. In her first year of life, she
suffered from recurrent ear and bladder infections. At 3 years
of age, she was hospitalized for pneumonia and was
leukopenic, with a white blood cell count of 2,800K ml1.
Thereafter, she continued to have recurrent lower urinary
tract infections and was placed on prophylactic antibiotics.
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Figure 1. Clinical findings and DNA analysis. (a) Fair skin and classic red hair in our patient, typical for oculocutaneous albinism type 4 patients. (b) Prominent
superficial venous pattern seen in all previously described G6PC3 mutation-positive neutropenia patients. (c) Pedigree showing affected and unaffected
individuals; our patient is depicted by the red box. Note the consanguineous background of the family. (d) Regions of homozygosity in the genome of the
patient (shown within red boxes). (e) Chromatogram of the mutation in SLC45A2 (c.986delC, p.T329RfsX68). (f) Chromatogram of the mutation in G6PC3
(c.829C4T, p.Q277X). Control sequences are shown for comparison. Photograph published with patient’s permission.
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Throughout childhood and adolescence, she had symptoms
of colitis, chronic abdominal pain, bloody diarrhea, recurrent
skin infections, easy bruising, and heavy menstrual periods. She
was eventually diagnosed with Crohn’s disease at 16 years of
age and failed medical therapy, resulting in a hemicolectomy at
17 years of age. Despite this surgery, she continued to have
symptoms of inflammatory bowel disease and has received
antibiotics and immunosuppressive therapy intermittently.
Because of her persistent cytopenias and history of
infections, the patient underwent a bone marrow aspiration
at 16 years of age that showed arrested neutrophil develop-
ment; granulocytic precursors were markedly increased
but matured only to the myelocyte and metamyelocyte stage.
The patient began receiving recombinant human granulocyte
colony-stimulating factor (Neupogen, Amgen, Thousand
Oaks, CA), resulting in improved neutrophil counts (Supple-
mentary Table S1 online) and fewer infections, especially
skin abscesses. The absolute neutrophil count at 29 years of
age was recorded as 0; neutrophil release and chemotaxis
tests were abnormal. The first report of significant thrombo-
cytopenia occurred at 29 years of age, with a platelet count of
94Kml1. Thereafter, platelet counts ranged from 21 to
57Kml1 and averaged 36.6 K ml1. Platelet aggregation
studies showed an abnormal secondary aggregation
response, with no response to mini-dose ADP or adrenaline.
However, whole-mount electron microscopy of her platelets
showed the presence of dense bodies. Despite her laboratory
abnormalities, the patient did not experience serious bleed-
ing, nor did she receive platelets or DDAVP (desmopressin
acetate), even with major surgeries such as an atrial septal
defect repair at 31 years of age.
Upon admission to the NIH at 32 years of age, the
proband underwent a screening examination that revealed
prognathism and abnormal skin findings. She had ecchy-
moses and petechiae on her extremities, an eczematous rash
on her upper extremities, and fine telangiectasias on her
arms and chest. A prominent superficial venous pattern was
present on her legs (Figure 1b). There was no evidence of skin
infections. Her eye exam was consistent with ocular
albinism, and her visual acuities were 20/160 in the right
eye and 20/800 in the left eye. Her pulmonary, liver, and
renal function tests were normal.
A hematological evaluation was performed to investigate
the cytopenias. Her total leukocyte and neutrophil counts
were low, but the remainder of her differential was normal,
and her red blood cell and reticulocyte indices were normal
(Supplementary Table S2 online). A peripheral smear showed
neutropenia; the granulocytes contained primary granules,
although some were hypogranular. Rare Dohle bodies were
also noted, and the platelets were enlarged.
Although the patient was receiving recombinant human
granulocyte colony-stimulating factor, the marrow aspirate
showed hypercellularity, myeloid hyperplasia with a left shift,
and increased megakaryocytes. The differential was 75%
myeloid precursors, 19% erythroid precursors, 5% lympho-
cytes, and 1% blasts. Primary granules persisted, and some
mature granulocytes had cytoplasmic vacuoles. Rare pelger-
oid bodies were noted; there was no stainable iron.
Other immunological, autoimmune, and infectious dis-
ease studies were normal. She had a minimal decrease in her
total immunoglobulin A level, but other tests of immune
competency were normal, and an assay for HIV was negative.
Her soluble IL-2R level was also normal. The antinuclear
antigen level, extractable nuclear antigen panel, and assays
for antibodies to platelets and neutrophils were all negative.
The patient’s parents were first cousins (Figure 1c).
Her brother had albinism, colitis, and a history of recurrent
infections. Although his medical history was similar to
the proband’s, he was never compliant with treatment and
became progressively more ill in his late 20 s and early 30 s,
resulting in a colostomy at 32 years of age. Afterward, he
developed recurrent infections and was non-compliant with
recombinant human granulocyte colony-stimulating factor
therapy. At 37 years of age, he was hospitalized for sepsis and
endocarditis, and died shortly afterward from multisystem
organ failure due to septic shock.
Molecular diagnostics
Owing to the presence of HPS-2-related symptoms of OCA,
bleeding and neutropenia, all coding exons and flanking
intronic sequences of AP3B1 were sequenced using conven-
tional dideoxy sequencing. No disease-causing mutations
were detected, and further analysis of mRNA and protein in
dermal fibroblasts and melanocytes revealed no change
in expression compared with control cells (data not shown).
As our current definition of HPS requires the absence of
platelet dense bodies, and this patient had a normal
contingent of d-granules, we considered the possibility that
this could represent a new disease.
SNP array analysis
The patient is a result of a first cousin union (Figure 1c),
so autosomal recessive inheritance was suspected. Therefore,
a SNP–chip microarray was carried out on the patient’s
genomic DNA to identify regions of her genome that were
homozygous and could harbor the disease-causing mutation.
Indeed, approximately B10% of her genome was homo-
zygous including the centromeric areas of chromosomes
4 and 5 (Figure 1d and Supplementary Figure S1 online).
These data, however, were not very informative, as the
regions of homozygosity were so large.
Whole-exome sequencing
We next subjected the patient’s DNA to whole-exome
sequencing. This technique covers the 1.22% of the human
genome corresponding to the Consensus Conserved Domain
Sequences database and greater than 1,000 non-coding
RNAs (Gnirke et al., 2009). After alignment of the patient’s
DNA sequence fragments to the UCSC reference genome
(build 18), there were 62,235 variations and after filtering
out known SNPs using dbSNP (http://www.ncbi.nlm.nih.gov/
snp/), there were 13,950 variants. This number was reduced
to 1502 variations after filtering for variants likely to affect
the protein sequence. After further filtering for regions of
homozygosity from the SNP–chip data, the number of
homozygous variations was reduced to 30 (Supplementary
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Table S3 online). From there, a candidate gene approach
was used to identify potentially pathogenic mutations using
the potential detriment (CD_Pred) score as a guide (Johnston
et al., 2010).
The most likely mutations identified were a known
mutation in G6PC3 (c.829C4T, p.Q277X), which had
previously been seen in a French patient (Boztug et al.,
2009), and a novel mutation in SLC45A2 (c.987delA,
p.A330PfsX68). Both of these mutations were in the expected
homozygous state. Conventional dideoxy sequencing of
G6PC3 confirmed the mutations and explained the patient’s
neutropenia (Figure 1f), but the mutation identified by whole-
exome sequencing for SLC45A2 was incorrect. The actual
mutation in SLC45A2 was c.986delC, p.T329RfsX68 (Figure
1e), a previously described mutation in five German OCA-4
patients (Rundshagen et al., 2004). An explanation for the
discrepancy would be the misalignment of the whole-exome
reads due to presence of a known SNP (rs2287949)
immediately after the deletion.
SLC45A2 and OCA
To ascertain whether the mutation in SLC45A2 was likely to
be pathogenic, expression analysis of mRNA and protein
was carried out. Quantitative real-time PCR showed
significantly reduced mRNA levels (14.1±1.24% compared
with control; Po0.001; Figure 2a). SLC45A2 protein was
undetectable in the patient’s melanocytes compared with
control cells by western blotting (Figure 2b). Immunofluor-
escence microscopy of normal human melanocytes revealed
punctate cytoplasmic staining for SLC45A2 that colocalized
to PMEL17-positive stage II melanosomes (Figure 2c). As the
patient had no detectable SLC45A2 protein expression,
no signal was seen in this channel, confirming the specificity
of the antibody. Nevertheless, the PMEL17 localization
appeared comparable to that of wild-type cells, suggesting
that biogenesis and trafficking of PMEL17-positive organelles
is not defective.
In normal melanocytes, tyrosinase predominantly loca-
lizes to PMEL17-positive cytoplasmic structures, whereas
in patient cells there was no colocalization (Figure 2d).
No endoplasmic reticulum (ER) or trans-Golgi network
retention of tyrosinase was observed in the patient’s
melanocytes, as seen in OCA-1 and OCA-3 cells (Halaban
et al., 2000; Toyofuku et al., 2001). In patient cells, tyrosinase
was primarily localized to the plasma membrane as observed
by immunofluorescence microscopy (Figure 2d) and specifi-
cally colocalized with the plasma membrane marker Nile red
(Figure 2f). Furthermore, after separation of plasma mem-
brane proteins by biotinylation before cell lysis, tyrosinase
was only found in the membrane fraction of patient cells
(Figure 2e). Expression of tyrosinase in the patient’s melano-
cytes was slightly reduced in whole-cell extracts compared
with control cells; tyrosinase was detectable only in the
growth medium of patient’s cells (Figure 2b). Furthermore,
isolating exosomes from the conditioned medium revealed
that the secreted tyrosinase was present in exosomes
(Figure 2b).
It is possible that tyrosinase and other proteins are being
secreted into the medium as a result of the reduced G6PC3
expression. However, Coomassie or silver staining of the gels
containing whole-cell lysates and conditioned medium
revealed that there were no differences in total amounts of
secreted proteins between patient and control (Supplemen-
tary Figure S2a and b online). This suggests that the aberrant
protein secretion is tyrosinase specific, and therefore likely
due to the SLC45A2 defect.
G6PC3 and neutropenia
The G6PC3 mutation was further investigated. Quantitative
real-time PCR revealed a significant reduction in the
expression of the transcript (5.47±0.75% compared with
control; Po0.001; Figure 3a), probably due to nonsense-
mediated decay. As G6PC3 deficiency is related to increased
spontaneous apoptosis due to ER stress (Cheung et al., 2007;
Boztug et al., 2009), we studied the rate of spontaneous
apoptosis in our patient’s fibroblasts. The percentage of
patient cells that were undergoing apoptosis was higher than
in control cells (23.8±2.3% for control and 27.1±1.2% for
patient; P¼ 0.14), but this difference was not statistically
significant (Figure 3b). However, when the cells were
subjected to ER stress using 5mM dithiothreitol, the percen-
tage of the patient’s cells undergoing apoptosis was
significantly greater than for control cells (91.5±1.1% vs
72.6±1.3%; Po0.001).
Figure 2. Functional analysis of the oculocutaneous albinism type 4 phenotype. (a) Quantitative real-time PCR results for SLC45A2 mRNA expression in
patient compared with control melanocytes. Values shown are percentage expression of SLC45A2 in patient cells compared with control cells, normalized by
ACTB (error bars¼±1 SEM, n¼3, Po0.001). (b) Western blots of whole-cell extracts (WCEs), conditioned medium, and exosome pellets from control and
patient melanocytes. There is no detectable SLC45A2 protein expression, and tyrosinase expression is reduced in patient cells compared with control cells.
Tyrosinase is present in the medium from patient cells, suggesting that this protein is abnormally secreted from these cells; it is also found in the excreted
exosome pellet. The media were collected from an equal number of cells, and equal volumes of concentrated proteins were loaded onto the gel. Loading
was controlled by assessing b-actin expression in the whole-cell lysate of the corresponding cells. The western blot with the exosome marker TSG101
demonstrates that exosomes were isolated from the conditioned medium. (c) Control and patient cells stained for SLC45A2 and the melanosome marker
PMEL17, showing colocalization (inserts) of the two proteins in control cells. Consistent with the western blot, no staining for SLC45A2 is seen in patient cells,
but PMEL17 looks comparable to control cells. (d) Control and patient cells stained for tyrosinase and PMEL17 show the colocalization (inserts) of the two
proteins in control cells. No colocalization is seen in patient cells, and tyrosinase appears predominantly in the plasma membrane. Nuclei are stained with
4’,6-diamidino-2-phenylindole; bar¼20 mm. (e) Plasma membrane protein biotinylation assay. Only the patient’s cells showed tyrosinase on the plasma
membrane. No b-actin was detected in the membrane fraction (demonstrating purity). Whole-cell lysates showed tyrosinase expression in control and patient
cells (loading controlled by b-actin). (f) High-magnification images of control and patient cells stained for tyrosinase and the plasma membrane marker Nile red.
Tyrosinase membrane localization in the patient is evidenced by the colocalization of tyrosinase and Nile red. Bar¼5 mm.
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DISCUSSION
The application of SNP array analysis, homozygosity map-
ping, and whole-exome sequencing to a patient with OCA
and neutropenia allowed us to diagnose two different
disorders in a single, unique patient. This was possible, in
part, because the patient was born from a consanguineous
mating. Furthermore, the identified mutations were present
in genes previously associated with similar phenotypes
(Rundshagen et al., 2004; Boztug et al., 2009), allowing for
greater confidence that these mutations are causing the
phenotypes seen in our patient.
One of the homozygous variants identified in our patient
involved SLC45A2, associated with OCA-4. Reduced mRNA
expression, consistent with nonsense-mediated decay, com-
bined with absence of SLC45A2 protein detected by western
blotting and immunofluorescence in cultured melanocytes,
strongly suggested that the SLC45A2 mutation c.986delC is
pathogenic. This case represents the first North American
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patient shown to have OCA-4, and to our knowledge, her
melanocytes are the only such cultures obtained from an
individual with OCA-4.
Relatively little is known about the function of SLC45A2 in
human melanocytes, although mutations in the gene were
identified as the cause of OCA-4 nearly a decade ago
(Newton et al., 2001). We showed that human SLC45A2-
deficient melanocytes exhibited a normal distribution of
PMEL17-tagged melanosomes, similar to what was observed
in the underwhite mouse model of OCA-4 (Costin et al.,
2003). We also demonstrated that, in our patient’s cells,
tyrosinase was mislocalized to the plasma membrane,
suggesting that SLC45A2 functions in the correct trafficking
of melanocyte-specific proteins to melanosomes, probably at
the level of trans-Golgi network sorting. Moreover, the
presence of tyrosinase in the growth medium of the patient’s
cells, and specifically in exosomes (Figure 2b), suggests that
tyrosinase is also prematurely secreted out of the cell without
passing through melanosomes. These findings explain the
hypopigmentation phenotype of OCA-4 and are consistent
with observations in melanocytes from the underwhite
OCA-4 mouse model (Costin et al., 2003). However, our
results should be interpreted with caution, as the patient’s
cells have a mutation in another disease-causing gene, with
unknown effects on melanocytes.
The second mutation in our patient involves G6PC3. Three
genes are known to encode enzymes that have glucose-6-
phosphatase activity, i.e., G6PC1, G6PC2, and G6PC3. All
three proteins have the same enzymatic activity, i.e., removal
of the phosphate group from glucose-6-phosphate to produce
glucose. G6PC1 is expressed in the liver, kidney, and small
intestine and catalyzes the essential hydrolysis of glucose-6-
phosphate in the gluconeogenic and glycogenolytic path-
ways (Lei et al., 1993). G6PC2 is expressed only in pancreatic
islet cells, where it is thought to function in glucose-
dependent insulin secretion by controlling free glucose levels
(Martin et al., 2001; Petrolonis et al., 2004). In contrast,
G6PC3 is ubiquitously expressed, as evidenced by a wide
range of affected tissues in patients with G6PC3 mutations.
For example, such patients have atrial septal defects and
low platelet counts (Boztug et al., 2009), features that
were also observed in our patient.
The G6PC3 mutation c.829C4T identified in our patient
was previously described in a French patient in the
heterozygous state (Boztug et al., 2009). However, as it is a
null allele, this mutation was not functionally investigated.
Furthermore, expression at the protein level could not be
assessed because there is no commercially available antibody
against G6PC3. We did demonstrate a reduction in G6PC3
mRNA expression in our patient’s cells (Figure 3a), consistent
with nonsense-mediated decay. This finding strongly implies
decreased protein expression as well. Functional G6PC3 is
required to maintain neutrophil viability; absence of the
enzyme results in reduced neutrophil number and increased
spontaneous apoptosis due to ER stress (Cheung et al., 2007;
Boztug et al., 2009). We demonstrated a higher rate of
spontaneous apoptosis in our patient’s fibroblasts compared
with control cells. If the same phenomenon were to occur in
neutrophils, the decreased G6PC3 protein expression could
explain the neutropenia. It could also account for the relative
paucity of mature neutrophils in the blood and bone marrow,
as the older cells may be more likely to undergo apoptosis
than survive.
Our patient’s inflammatory bowel disease could not
readily be attributed to either SLC45A2 or G6PC3 mutations,
but may be related to another mutated gene due to
consanguinity.
Syndromic, multisystemic pigmentary disorders are
excellent examples of diseases whose identification can be
difficult, especially when consanguinity introduces the
possible involvement of multiple genes. One approach in
this situation is to perform homozygosity mapping based upon
SNP array results, followed by whole-exome sequencing.
MATERIALS AND METHODS
Patient
The patient was enrolled in protocol 76-HG-0238 (http://www.
clinicaltrials.gov, NCT00369421), ‘‘Diagnosis and Treatment of
Inborn Errors of Metabolism’’, approved by the NHGRI Institutional
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Figure 3. Functional analysis of the G6PC3 phenotype. (a) Quantitative
real-time PCR results for G6PC3 mRNA expression in patients compared
with control melanocytes. Values shown are percentage expression of G6PC3
in patient cells compared with control cells, normalized by ACTB (error
bars¼±1 SEM, n¼ 3, Po0.001). (b) Flow cytometry results using the
Annexin V apoptosis assay for control and patient cells with and without
endoplasmic reticulum stress induction (error bars¼±1 SEM, n¼ 3). Without
5mM dithiothreitol treatment, no significant difference can be seen; with
treatment, there is a clear increase in apoptosis in patient cells.
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Review Board. Written, informed consent was obtained in adher-
ence to the Declaration of Helsinki Principles.
SNP arrays and dideoxy sequencing
For SNP genotyping, genomic DNA was run on a Human 1M-Duo
DNA Analysis BeadChip and the data analyzed using the Geno-
meStudio software (both from Illumina, San Diego, CA). For dideoxy
sequencing, primers were designed to cover all coding exons
and flanking intronic regions of AP3B1, G6PC3, and SLC45A2
(primer sequences available upon request). Direct sequencing was
carried out using the dideoxy termination method (ABI BigDye
Terminator v3.1) on an ABI 3130xl DNA sequencer (Applied
Biosystems, Austin, TX). Results were analyzed using Sequencher
v4.9 software (Gene Codes, Ann Arbor, MI). All mutations were
verified bidirectionally.
Whole-exome sequencing and variant analysis
Solution hybridization exome capture was carried out using the
SureSelect Human All Exon System (Agilent Technologies, Santa
Clara, CA), which employs biotinylated RNA baits to hybridize to
sequences that correspond to exons. The manufacturer’s protocol
version 1.0 compatible with Illumina paired-end sequencing
was used, with the exception that DNA fragment size and quality
was measured using a 2% agarose gel stained with SYBR Gold
(Invitrogen, Carlsbad, CA) instead of using an Agilent Bioanalyzer.
Flowcell preparation and 101-bp paired-end read sequencing were
carried out as per protocol for the GAIIx sequencer (Illumina;
Bentley et al., 2008). A single 101-bp paired-end lane on a GAIIx
flowcell was used per exome sample to generate sufficient reads to
align the sequence. Image analysis and base calling on all lanes of
data were performed using Illumina Genome Analyzer Pipeline
software (GAPipeline versions 1.4.0 or greater) with default
parameters. Reads were aligned to a human reference sequence
(UCSC assembly hg18, NCBI build 36) using the package
called Efficient Large-scale Alignment of Nucleotide Databases
(Illumina, San Diego, CA). Genotypes were called at all positions
where there were high-quality sequence bases using a Bayesian
algorithm called the Most Probable Genotype (Teer et al., 2010).
A graphical java tool VarSifter was developed by NISC to view, sort,
and filter the variants.
Tissue culture
Primary patient and control fibroblasts and melanocytes were
cultured from a forearm skin biopsy. Fibroblasts were grown in
high-glucose (4.5 g l1) DMEM medium supplemented with 10%
fetal bovine serum, 2mM L-glutamine, MEM non-essential amino
acid solution, and penicillin–streptomycin. Melanocytes were
cultured in Ham’s F10 (Invitrogen, Carlsbad, CA), supplemented
with 5% fetal calf serum (Gemini Bio-Products, West Sacramento,
CA), 5mg l1 basic fibroblast growth factor (Sigma, St Louis, MO),
10 mg l1 Endothelin (Sigma), 7.5mg l1 3-Isobutyl-1-methylxanthine
(Sigma), 30 mg l1 Choleratoxin (Sigma), 3.3 mg l1 Phorbol 12-
myristate 13-acetate (Sigma), and 1ml Fungizone (Invitrogen).
Protein extraction and immunoblotting
Cells were grown to confluency in 25-cm2 flasks, washed twice with
ice-cold phosphate-buffered saline, and scraped into 250ml of cell
lysis buffer containing 50mM Tris-HCl (at pH 7.5), 50mM sodium
fluoride, 5mM sodium pyrophosphate, 1mM sodium orthovanadate,
1mM EDTA, 1mM EGTA, 0.27 M sucrose, 1% Triton X-100, and
Complete, Mini Protease Inhibitor Cocktail (Roche Diagnostics,
Indianapolis, IN). Cell lysates were centrifuged (15,000 g, for
15minutes at 4 1C); supernatants were removed for immunoblotting
or plasma membrane protein biotinylation experiments. Twenty
micrograms of total protein, as determined by the Dc Protein assay
(BioRad, Hercules, CA), were loaded onto 4–20% Tris–glycine gels.
After blotting, the PVDF membranes (Invitrogen) were probed with
a rabbit polyclonal antibody against SLC45A2 (Proteintech, Chicago,
IL) or mouse monoclonal antibodies against tyrosinase (clone T311;
Santa Cruz Biotechnology, Santa Cruz, CA) and TSG101 (clone
4A12; Abcam, Cambridge, MA). A mouse monoclonal antibody
against b-actin was used as a loading control (clone AC-15; Sigma).
HRP-labeled secondary anti-mouse or anti-rabbit antibodies were
used (Amersham Biosciences, Piscataway, NJ). The antigen–antibody
complexes were detected with an Enhanced Chemiluminescence kit
(Amersham Biosciences).
Conditioned medium and exosome isolation
To prepare serum-free conditioned medium, 3 106 cells per flask
were washed three times and incubated for 24 hours at 37 1C with
15ml serum-free culture medium. The medium was harvested and
centrifuged at 1,250 g for 10minutes at 4 1C. The supernatant was
ultracentrifuged at 200,000 g for 60minutes to isolate exosomes.
The exosome pellets were re-suspended in 2 Laemmli loading
buffer. The supernatant was 30 concentrated at 4 1C in Centriprep
YM-10 tubes (Millipore, Billerica, MA). The resulting protein
concentrates, exosome pellets, and whole-cell extracts from the
corresponding cells were subjected to western blotting as above.
Plasma membrane protein biotinylation
For membrane protein biotinylation, control and patient melano-
cytes were incubated with 500 ml of 0.25mgml1 EZ-Link Sulfo-
NHS-SS-Biotin (Thermo Scientific, Waltham, MA) for 30minutes at
4 1C. This reaction was quenched by incubating with 1M NH4Cl for
5minutes. Protein was then extracted using the protocol above. The
biotin-labeled proteins were separated from the total lysates using
streptavidin Dynabeads (Invitrogen) according to the manufacturer’s
instructions. The protein samples were loaded directly onto SDS-
PAGE gels for immunoblotting analysis.
Quantitative real-time PCR
Total RNA was isolated using RNA-Easy Mini-Kit (Qiagen, Valencia,
CA) according to the manufacturer’s protocol. RNA was treated with
a DNase kit (DNA-free) to remove all remaining DNA according to
the manufacturer’s protocol (Applied Biosystems). RNA concentra-
tion and purity were measured on the Nanodrop ND-1000 apparatus
(Nanodrop Technologies, Wilmington, DE). First-strand comple-
mentary DNA was synthesized using a high capacity RNA-to-cDNA
kit (Applied Biosystems) according to the manufacturer’s guidelines.
Taqman gene expression master mix reagent and Assays-On-
Demand (Applied Biosystems) were obtained for G6PC3 (assay ID
Hs00292720_m1), SLC45A2 (assay ID Hs01125486_m1), and a
control gene ACTB (assay ID Hs99999903_m1). Quantitative real-
time PCR was performed using 100 ng complementary DNA, on
an ABI PRISM 7900 HT Sequence Detection System (Applied
Biosystems) using the comparative CT method (DDCT); this method
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measures relative gene expression (Livak and Schmittgen, 2001). The
cycling conditions were as follows: 2minutes at 50 1C, 10minutes
at 95 1C, and 40 cycles at 95 1 C for 15 seconds and 60 1C for
60 seconds.
Immunofluorescence microscopy
Cells were grown in 4-well chamber slides and fixed using 4%
paraformaldehyde and permeabilized using 0.1% Triton X-100.
Antibodies against SLC45A2 and tyrosinase were purchased for
immunoblotting. A mouse monoclonal antibody (clone HMB45)
and a rabbit polyclonal against PMEL17 were purchased from
LifeSpan BioSciences (Seattle, WA) and Neomarkers (Fremont, CA),
respectively. Alexa Fluor 488 and 555 secondary antibody con-
jugates and Nile red were purchased from Invitrogen, and nuclei
were counterstained with 4’,6-diamidino-2-phenylindole (DAPI).
Cells were imaged with a Zeiss 510 META confocal laser-scanning
microscope (Carl Zeiss, Thornwood, NY), with the pinhole set to 1
airy unit. A series of optical sections were collected from the xy
plane and merged into maximum projection images.
Apoptosis assay
Spontaneous apoptosis was measured using the Annexin V and
propidium iodide apoptosis assay (Pigault et al., 1994). The Annexin
V-FITC apoptosis detection kit was purchased from Sigma, and the
assay carried out according to the manufacturer’s instructions with
5 105 fibroblast cells per treatment group. ER stress was induced
with 5mM dithiothreitol (Sigma) for 2 hours at 37 1C. The samples
were sorted on a Becton Dickenson FACSCalibur flow cytometer
(Franklin Lakes, NJ), on which green and red fluorescence were
counted. Data were analyzed using FlowJo software (Tree Star,
Ashland, OR).
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